Adhera Therapeutics, Inc. elected Zahed Subhan PhD MBA JD as Chairman of the Board. Dr. Subhan has been serving as a Company Director since November 5, 2021, and has more than 35 years' experience in research, development and commercialization in multinational pharmaceutical companies, including Sanofi, GlaxoSmithKline, Dupont Pharmaceuticals, and as Senior Management/CEO of both public and privately held biotechnology companies.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0039 USD | +2.63% | -13.33% | -87.00% |
1st Jan change | Capi. | |
---|---|---|
-87.00% | 45.34K | |
+15.37% | 121B | |
+13.34% | 107B | |
-5.06% | 24.82B | |
+1.69% | 22.48B | |
-10.09% | 18.32B | |
-40.52% | 16.33B | |
-14.69% | 15.31B | |
+3.13% | 14.08B | |
+26.04% | 11.74B |
- Stock Market
- Equities
- ATRX Stock
- News Adhera Therapeutics, Inc.
- Adhera Therapeutics, Inc. Elects Zahed Subhan as Chairman of the Board